Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
Construction of the plant will commence in 2025 with first production expected to be in 2027
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
The net-zero target approval complements the company's near-term emission reduction targets
Subscribe To Our Newsletter & Stay Updated
